Measuring the frequency of latent HIV-1 in resting CD4+ T cells using a limiting dilution coculture assay

Gregory Laird, Daniel I S Rosenbloom, Jun Lai, Robert F Siliciano, Janet M Siliciano

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Combination antiretroviral therapy (cART) can reduce HIV-1 viremia to clinically undetectable levels. However, replication competent virus persists in a long-lived latent reservoir n resting, memory CD4+ T cells. The latent reservoir in resting CD4+ T cells is the major barrier to curing HIV-1 infection. The recent case of the Berlin patient has suggested that it may be possible to cure HIV-1 infection in certain situations. As efforts to cure HIV-1 infection progress, it will become critical to measure the latent reservoir in patients participating in clinical trials of eradication strategies. Our laboratory has developed a limiting dilution virus outgrowth assay that can be used to demonstrate the presence and persistence of latent HIV-1 in patients. Here we describe both the original and a simplified version of the quantitative virus outgrowth assay (QVOA) to measure the frequency of latently infected resting CD4+ T cells with replication competent provirus in patients on suppressive cART.

Original languageEnglish (US)
Title of host publicationMethods in Molecular Biology
PublisherHumana Press Inc.
Pages239-253
Number of pages15
Volume1354
DOIs
StatePublished - 2016

Publication series

NameMethods in Molecular Biology
Volume1354
ISSN (Print)10643745

Fingerprint

Coculture Techniques
HIV-1
T-Lymphocytes
HIV Infections
Viruses
Proviruses
Viremia
Berlin
Virus Replication
Clinical Trials
Therapeutics

Keywords

  • HIV-1
  • Latency
  • Latent reservoir
  • Viral outgrowth assay

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics

Cite this

Laird, G., Rosenbloom, D. I. S., Lai, J., Siliciano, R. F., & Siliciano, J. M. (2016). Measuring the frequency of latent HIV-1 in resting CD4+ T cells using a limiting dilution coculture assay. In Methods in Molecular Biology (Vol. 1354, pp. 239-253). (Methods in Molecular Biology; Vol. 1354). Humana Press Inc.. https://doi.org/10.1007/978-1-4939-3046-3_16

Measuring the frequency of latent HIV-1 in resting CD4+ T cells using a limiting dilution coculture assay. / Laird, Gregory; Rosenbloom, Daniel I S; Lai, Jun; Siliciano, Robert F; Siliciano, Janet M.

Methods in Molecular Biology. Vol. 1354 Humana Press Inc., 2016. p. 239-253 (Methods in Molecular Biology; Vol. 1354).

Research output: Chapter in Book/Report/Conference proceedingChapter

Laird, G, Rosenbloom, DIS, Lai, J, Siliciano, RF & Siliciano, JM 2016, Measuring the frequency of latent HIV-1 in resting CD4+ T cells using a limiting dilution coculture assay. in Methods in Molecular Biology. vol. 1354, Methods in Molecular Biology, vol. 1354, Humana Press Inc., pp. 239-253. https://doi.org/10.1007/978-1-4939-3046-3_16
Laird G, Rosenbloom DIS, Lai J, Siliciano RF, Siliciano JM. Measuring the frequency of latent HIV-1 in resting CD4+ T cells using a limiting dilution coculture assay. In Methods in Molecular Biology. Vol. 1354. Humana Press Inc. 2016. p. 239-253. (Methods in Molecular Biology). https://doi.org/10.1007/978-1-4939-3046-3_16
Laird, Gregory ; Rosenbloom, Daniel I S ; Lai, Jun ; Siliciano, Robert F ; Siliciano, Janet M. / Measuring the frequency of latent HIV-1 in resting CD4+ T cells using a limiting dilution coculture assay. Methods in Molecular Biology. Vol. 1354 Humana Press Inc., 2016. pp. 239-253 (Methods in Molecular Biology).
@inbook{6a66fbb34b2f4332a8c62dd8d2e0607d,
title = "Measuring the frequency of latent HIV-1 in resting CD4+ T cells using a limiting dilution coculture assay",
abstract = "Combination antiretroviral therapy (cART) can reduce HIV-1 viremia to clinically undetectable levels. However, replication competent virus persists in a long-lived latent reservoir n resting, memory CD4+ T cells. The latent reservoir in resting CD4+ T cells is the major barrier to curing HIV-1 infection. The recent case of the Berlin patient has suggested that it may be possible to cure HIV-1 infection in certain situations. As efforts to cure HIV-1 infection progress, it will become critical to measure the latent reservoir in patients participating in clinical trials of eradication strategies. Our laboratory has developed a limiting dilution virus outgrowth assay that can be used to demonstrate the presence and persistence of latent HIV-1 in patients. Here we describe both the original and a simplified version of the quantitative virus outgrowth assay (QVOA) to measure the frequency of latently infected resting CD4+ T cells with replication competent provirus in patients on suppressive cART.",
keywords = "HIV-1, Latency, Latent reservoir, Viral outgrowth assay",
author = "Gregory Laird and Rosenbloom, {Daniel I S} and Jun Lai and Siliciano, {Robert F} and Siliciano, {Janet M}",
year = "2016",
doi = "10.1007/978-1-4939-3046-3_16",
language = "English (US)",
volume = "1354",
series = "Methods in Molecular Biology",
publisher = "Humana Press Inc.",
pages = "239--253",
booktitle = "Methods in Molecular Biology",

}

TY - CHAP

T1 - Measuring the frequency of latent HIV-1 in resting CD4+ T cells using a limiting dilution coculture assay

AU - Laird, Gregory

AU - Rosenbloom, Daniel I S

AU - Lai, Jun

AU - Siliciano, Robert F

AU - Siliciano, Janet M

PY - 2016

Y1 - 2016

N2 - Combination antiretroviral therapy (cART) can reduce HIV-1 viremia to clinically undetectable levels. However, replication competent virus persists in a long-lived latent reservoir n resting, memory CD4+ T cells. The latent reservoir in resting CD4+ T cells is the major barrier to curing HIV-1 infection. The recent case of the Berlin patient has suggested that it may be possible to cure HIV-1 infection in certain situations. As efforts to cure HIV-1 infection progress, it will become critical to measure the latent reservoir in patients participating in clinical trials of eradication strategies. Our laboratory has developed a limiting dilution virus outgrowth assay that can be used to demonstrate the presence and persistence of latent HIV-1 in patients. Here we describe both the original and a simplified version of the quantitative virus outgrowth assay (QVOA) to measure the frequency of latently infected resting CD4+ T cells with replication competent provirus in patients on suppressive cART.

AB - Combination antiretroviral therapy (cART) can reduce HIV-1 viremia to clinically undetectable levels. However, replication competent virus persists in a long-lived latent reservoir n resting, memory CD4+ T cells. The latent reservoir in resting CD4+ T cells is the major barrier to curing HIV-1 infection. The recent case of the Berlin patient has suggested that it may be possible to cure HIV-1 infection in certain situations. As efforts to cure HIV-1 infection progress, it will become critical to measure the latent reservoir in patients participating in clinical trials of eradication strategies. Our laboratory has developed a limiting dilution virus outgrowth assay that can be used to demonstrate the presence and persistence of latent HIV-1 in patients. Here we describe both the original and a simplified version of the quantitative virus outgrowth assay (QVOA) to measure the frequency of latently infected resting CD4+ T cells with replication competent provirus in patients on suppressive cART.

KW - HIV-1

KW - Latency

KW - Latent reservoir

KW - Viral outgrowth assay

UR - http://www.scopus.com/inward/record.url?scp=84952913716&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952913716&partnerID=8YFLogxK

U2 - 10.1007/978-1-4939-3046-3_16

DO - 10.1007/978-1-4939-3046-3_16

M3 - Chapter

VL - 1354

T3 - Methods in Molecular Biology

SP - 239

EP - 253

BT - Methods in Molecular Biology

PB - Humana Press Inc.

ER -